Analysis of quality of life indicators using various questionnaires in patients with idiopathic pulmonary hypertension.

Idiopathic pulmonary hypertension (IPAH) is a rare severe disease with a poor prognosis. Assessing quality of life (QoL) using questionnaires can significantly complement clinical, laboratory and instrumental data. Aim. To assess QoL using various questionnaires in patients with a newly and previously diagnosed IPAH. Materials and methods. 73 patients with IPAH were included in the study, all patients filled out Qol questionnaires: universal (SF-36, EQ-5D-3L) and special for patients with pulmonary hypertension (CAMPHOR, PAH-SYMPACT, EmPHasis-10). Two groups were formed, comparable by age and gender: group 1-42 patients with newly diagnosed IPAH; group 2-31 patients with a previously diagnosed IPAH. Results. Significant differences in SF-36 were found in the scale of Mental Health (52 [40; 64] % in the first group and 60 [52; 80] % in the second, p=0,02) and Mental component summary (40,8 [34,3; 49,3] % and 49,1 [41,0; 55,9] %, respectively, p=0,03). According to the EQ-5D-3L results, differences were found in the Visual Analogue Scale (VAS) and EQ-5D Index: higher values were found in the second group (the median VAS score was 50 [40; 60] % in the first group and 60 [50; 70] % in the second, p=0,006, EQ-5D Index – 0,60 [0,30; 0,71] and 0,66 [0,57; 0,76], respectively, p=0,05). No significant differences were found in the results of CAMPHOR, PAH-SYMPACT, and EmPHasis-10 in two groups. Conclusions. Pathogenetic therapy promotes improvement of functional status of patients with IPAH. Low emotional status indicators in patients with a prevalent disease indicates the need to develop a system of psychological assistance for IPAH patients.

1. Авдеев С.Н., Барбараш О.Л., Валиева З.С., Волков А.В., Веселова Т.Н., Галявич А.С., Гончарова Н.С., Горбачевский С.В., Грамович В.В., Данилов Н.М., Клименко А.А., Мартынюк Т.В., Моисеева О.М., Рыжкова Д.В., Симакова М.А., Синицын В.Е., Стукалова О.В., Чазова И.Е., Черногривов И.Е., Шмальц А.А., Царева Н.А. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6161. https://doi.org/10.15829/1560-4071-2024-6161 [Avdeev S.N., Barbarash O.L., Valieva Z.S., Volkov A.V., Veselova T.N., Galyavich A.S., Goncharova N.S., Gorbachevsky S.V., Gramovich V.V., Danilov N.M., Klimenko A.A., Martynyuk T.V., Moiseeva O.M., Ryzhkova D.V., Simakova M.A., Sinitsyn V.E., Stukalova O.V., Chazova I.E., Chernogrivov I.E., Shmalts A.A., Tsareva N.A. 2024 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6161 ]

2. Чазова И.Е., Мартынюк Т.В., Шмальц А.А., Грамович В.В., Данилов Н.М., Веселова Т.Н., Коробкова И.З., Сарыбаев А.Ш., Стукалова О.В., Азизов В.А., Барбараш О.Л., Галявич А.С., Горбачевский С.В., Медведева Е.А., Матчин Ю.Г., Мукаров М.А., Наконечников С.Н., Филиппов Е.В., Черногривов И.Е. Евразийские рекомендации по диагностике и лечению лёгочной гипертензии (2023). Евразийский Кардиологический Журнал. 2024;(1):6-85. https://doi.org/10.38109/2225-1685-2024-1-6-85 [Chazova I.E., Martynyuk T.V., Shmalts A.A., Gramovich V.V., Danilov N.M., Veselova T.N., Korobkova I.Z., Sarybaev A.Sh., Stukalova O.V., Azizov V.A., Barbarash O.L., Galyavich A.S., Gorbachevsky S.V., Medvedeva E.A., Matchin Yu.G., Mukarov M.A., Nakonechnikov S.N., Filippov E.V., Chernogrivov I.E. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023). Eurasian heart journal. 2024;(1):6-85. (In Russ.) https://doi.org/10.38109/2225-1685-2024-1-6-85 ]

3. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, VachieryL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. https://doi.org/10.1093/eurheartj/ehac237

4. Легочная гипертензия/ Под ред. И.Е. Чазовой и Т.В. Мартынюк. – М.: Практика, 2015.– 928 с. ISBN 978-5-89816-138-5 [Pulmonary hypertension/ Edited by I.E. Chazova and T.V. Martynyuk. – M.: Praktika, 2015.– 928 p. ISBN 978-5-89816-138-5]

5. Gilbert E. D'Alonzo, Robyn J. Barst, Stephen M. Ayres, et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry. Ann Intern Med.1991;115:343-349. https://doi.org/10.7326/0003-4819-115-5-343

6. Benza R.L., Miller D.P., Barst R.J. et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–456. https://doi.org/10.1378/chest.11-1460.

7. Ford HJ, Brunetti C, Ferrari P, Meszaros G, Moles VM, Skaara H, Torbicki A, Gibbs JSR. Exploring the patient perspective in pulmonary hypertension. Eur Respir J. 2024 Oct 31;64(4):2401129. https://doi.org/10.1183/13993003.01129-2024

8. Николаева Е.А., Валиева З.С., Мартынюк Т.В. Оценка качества жизни у пациентов с легочной артериальной гипертензией. Системные гипертензии. 2024;21(3):41-46. https://doi.org/10.38109/2075-082X-2024-3-41-46 [Nikolaeva E.A., Valieva Z.S., Martynyuk T.V. Quality of life аssessment in patients with pulmonary arterial hypertension. Systemic Hypertension. 2024;21(3):41-46. (In Russ.) https://doi.org/10.38109/2075-082X-2024-3-41-46 ]

9. Chazova IY, Martynyuk TV, Valieva ZS, Gratsianskaya SY, Aleevskaya AM, Zorin AV, Nakonechnikov SN. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. Biomed Res Int. 2020 Jun 14;2020:6836973. https://doi.org/10.1155/2020/6836973

10. Шостак Н.А., Клименко А.А., Шеменкова В.С., Свет А.В. Использование опросника SF-36 в оценке качества жизни у пациентов с хронической тромбоэмболической легочной гипертензией. Клиницист. 2017;11(3-4):44-49. https://doi.org/10.17650/1818-8338-2017-11-3-4-44-49 [Shostak N.A., Klimenko A.N., Shemenkova V.S., Svet A.V. Use of the SF-36 questionnare in assessment of quality of life in patients with chronic thromboembolic pulmonary hypertension. The Clinician. 2017;11(3-4):44-49. (In Russ.) https://doi.org/10.17650/1818-8338-2017-11-3-4-44-49 ]

11. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1;347(5):322-9. https://doi.org/10.1056/NEJMoa020204

12. Reis A, Santos M, Vicente M, Furtado I, Cruz C, Melo A, Carvalho L, Gonçalves F, Sa-Couto P, Almeida L. Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross Sectional Study. Biomed Res Int. 2018 Mar 19;2018:3924517. https://doi.org/10.1155/2018/3924517

13. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, Church AC, Coghlan JG, Davies RJ, Dimopoulos K, Elliot C, Gibbs JSR, Gin-Sing W, Haji G, Hameed AG, Howard LS, Johnson MK, Kempny A, Kiely DG, Lo Giudice F, McCabe C, Peacock AJ, Peleyeju O, Pepke-Zaba J, Polwarth G, Price L, Sabroe I, Schreiber BE, Sheares K, Taboada D, Thompson AAR, Toshner MR, Wanjiku I, Wort SJ, Yorke J, Condliffe R. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. Eur Respir J. 2021 Feb 25;57(2):2000124. https://doi.org/10.1183/13993003.00124-2020

14. Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018 Oct;154(4):848-861. https://doi.org/10.1016/j.chest.2018.04.027

15. Sarzyska K, Świątoniowska-Lonc N, Dudek K, et al. Quality of life of patients with pulmonary arterial hypertension: a meta-analysis. Eur Rev Med Pharmacol Sci 2021;25:4983-4998. https://doi.org/10.26355/eurrev_202108_26455

16. Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT; PHAR Study Group. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 Feb 25;57(2):2000414. https://doi.org/10.1183/13993003.00414-2020. Erratum in: Eur Respir J. 2025 Jun 5;65(6):2050414. https://doi.org/10.1183/13993003.50414 2020